AYTU BIOPHARMA, INC
For the period ended Nov 13, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 13, 2025 · Filed Nov 13, 2025
Use the contents to explore the available documents and sections.
AYTU$1.83+1.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share data)
(in thousands, except share data)
| September 30, | June 30, | |
|---|---|---|
| 2025 | 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $32,630 | $30,952 |
| Accounts receivable, net | 33,225 | 31,155 |
| Inventories | 10,100 | 11,434 |
| Prepaid expenses and other current assets | 5,154 | 5,638 |
| Total current assets | 81,109 | 79,179 |
| Non-current assets: | ||
| Property and equipment, net | 500 | 532 |
| Operating lease right-of-use assets | 1,010 | 1,061 |
| Intangible assets, net | 41,430 | 42,201 |
| Other non-current assets | 939 | 1,204 |
| Total non-current assets | 43,879 | 44,998 |
| Total assets | $124,988 | $124,177 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $12,342 | $10,601 |
| Accrued liabilities | 36,700 | 38,164 |
| Revolving credit facility | 14,873 | 9,063 |
| Current portion of debt | 1,857 | 1,857 |
| Other current liabilities | 221 | 3,379 |
| Total current liabilities | 65,993 | 63,064 |
| Non-current liabilities: | ||
| Debt, net of current portion | 10,447 | 10,895 |
| Derivative warrant liabilities | 20,424 | 26,334 |
| Other non-current liabilities | 4,953 | 4,918 |
| Total non-current liabilities | 35,824 | 42,147 |
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 50,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, par value $0.0001; 200,000,000 shares authorized; 9,911,913 and 8,976,913 shares issued and outstanding, respectively | 1 | 1 |
| Additional paid-in capital | 354,740 | 352,500 |
| Accumulated deficit | (331,570) | (333,535) |
| Total stockholders’ equity | 23,171 | 18,966 |
| Total liabilities and stockholders’ equity | $124,988 | $124,177 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.